Evaluation of Thrombocytopaenia-Related Complications After Bioprosthetic Aortic Valve Implantation

Abstract

Introduction:We aimed to determine whether thrombocytopaenia (TCP) is associated with postoperative complications in patients undergoing bioprosthetic aortic valve replacement.Patients and Methods: Clinical records of 39 consecutive patients undergoing bioprosthetic aortic valve replacement for aortic stenosis were reviewed. Patients were divided into 2 groups based on whether they had TCP or not within 7 days after the operation [TCP (+), 9 patients and TCP (-), 30 patients]. TCP was defined as a platelet count less than 50 × 10 9 /L.Results: Both the groups were similar with regard to baseline clinical characteristics and operative variables. Stentless bioprosthesis was used in 16 patients (41.02%). The use of Sorin Pericarbon Freedom was significantly more common in the TCP (+) group. Postoperative complications such as the removal time of the drainage tube, intensive care unit (ICU) stay and acute renal failure were significantly higher in the TCP (+) group. Overall, 30-day mortality occurred in 3 (7.7%) patients, and the difference between the groups was not statistically significant. Conclusion:Postoperative TCP may be associated with a substantial threat for the postoperative status of patients undergoing bioprosthetic valve replacement. The issue is still subject to further research until the exact mechanism underlying its occurrence is elucidated.